Clinical trials: Perennial Allergic Rhinitis (PAR), open to volunteers
Perennial Allergic Rhinitis (PAR)
Study of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background Therapy
This is a randomized, double-blind, placebo-parallel controlled phase II study to evaluate the safety and efficacy of CM512 in patients with perennial allergic rhinitis on background therapy
- Trial name
- NCT07890350
- Testing
- CM512
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing Keymed Biosciences Co., Ltd.